US20230320981A1 - Solid oral pharmaceutical compositions for isoxazoline compounds - Google Patents

Solid oral pharmaceutical compositions for isoxazoline compounds Download PDF

Info

Publication number
US20230320981A1
US20230320981A1 US18/335,415 US202318335415A US2023320981A1 US 20230320981 A1 US20230320981 A1 US 20230320981A1 US 202318335415 A US202318335415 A US 202318335415A US 2023320981 A1 US2023320981 A1 US 2023320981A1
Authority
US
United States
Prior art keywords
solvent
pharmaceutical composition
compound
composition
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/335,415
Inventor
Keith Freehauf
Niki Waldron
Jürgen Lutz
Frank Guerino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet Inc
Original Assignee
Intervet Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49300034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20230320981(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Inc filed Critical Intervet Inc
Priority to US18/335,415 priority Critical patent/US20230320981A1/en
Assigned to INTERVET INC. reassignment INTERVET INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LUTZ, JURGEN, FREEHAUF, KEITH, GUERINO, FRANK, WALDRON, NIKI
Assigned to INTERVET INC. reassignment INTERVET INC. CHANGE OF ADDRESS Assignors: INTERVET INC.
Publication of US20230320981A1 publication Critical patent/US20230320981A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • a number of parasites can infest or infect domestic animals especially also companion animals such as cats and dogs. These pests and parasites are of great nuisance to both the animals and their owners.
  • Isoxazoline compounds are known in the art and these compounds and their use as antiparasitic are described, for example, in US patent application US 2007/0066617, and International Patent applications WO 2005/085216, WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO 2009/080250, WO 2010/070068 and WO 2010/079077, the disclosures of which, as well as the references cited herein, are incorporated by reference.
  • This class of compounds is known to possess excellent activity against ectoparasites, i.e. parasitic insect and acarids, such as ticks and fleas and endoparasites such as nematodes.
  • isoxazoline compounds are carbamoyl benzamide phenyl isoxazoline (CBPI) compounds.
  • CBPI carbamoyl benzamide phenyl isoxazoline
  • a specific example of a CBPI compound is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN [864731-61-3])—USAN fluralaner.
  • the CBPI compound fluralaner is disclosed in patent application WO 2005/085216.
  • One known and convenient way of administering an ectoparasiticide compound to an animal is oral administration, e.g. as solid oral formulation such as tablets or soft chews that have a high bioavailability to allow the control of parasites with a low dosage of the ectoparasiticide compound orally administered to the animal.
  • the current invention is directed to a solid oral pharmaceutical composition
  • a solid oral pharmaceutical composition comprising an effective amount of at least one isoxazoline compound of the Formula (I)
  • the solid oral pharmaceutical composition is a soft chewable veterinary pharmaceutical composition for oral administration.
  • the solid carrier is microcrystalline cellulose.
  • composition further comprises pamoic acid or a pharmaceutically acceptable salt thereof.
  • the isoxazoline compound is fluralaner.
  • the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N—[(Z)-(methoxyimino)methyl]-2-methyl-benzamide.
  • the isoxazoline compound is afoxolaner.
  • the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide.
  • the isoxazoline compound is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide.
  • the solid oral pharmaceutical composition comprises an additional pharmaceutically active compound.
  • the additional pharmaceutically active compound is a macrocyclic lactone selected from the group of ivermectin, milbemycin, and moxidectin.
  • the solid oral pharmaceutical composition comprises an isoxazoline compound of Formula (I) or a salt or solvate thereof, 2-pyrrolidone, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, sodium pamoate, magnesium stearate, aspartame, glycerol, soybean oil, and polyethylene glycol
  • the solid oral pharmaceutical composition comprises an isoxazoline compound of Formula (I) or a salt or solvate thereof, dimethyl acetamide, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, sodium pamoate, magnesium stearate, aspartame, glycerol, soybean oil, and polyethylene glycol.
  • Another aspect of the invention is a method of preparing a solid pharmaceutical composition comprising dissolving the isoxazoline compound as above in the solvent and then adsorbing the resulting solution on to the solid carrier excipient.
  • the solid carrier is microcrystalline cellulose.
  • the solvent is 2-pyrrolidone or dimethyl acetamide.
  • Another aspect of the current invention is a method of controlling parasite infestation in an animal comprising administering to the animal a therapeutically effective amount of the composition as described above.
  • Another aspect of the current invention is a solid oral pharmaceutical composition
  • a solid oral pharmaceutical composition comprising an isoxazoline compound of Formula (I) or a salt or solvate thereof, and 2-pyrrolidone.
  • the isoxazoline compound is fluralaner.
  • the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N—[(Z)-(methoxyimino)methyl]-2-methyl-benzamide.
  • the isoxazoline compound is afoxolaner.
  • the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide.
  • the isoxazoline compound is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide.
  • the solid oral pharmaceutical composition is a soft chewable veterinary pharmaceutical composition for oral administration.
  • Another aspect of the current invention is a method of controlling parasite infestation in an animal comprising administering to the animal a therapeutically effective amount of the composition as described above.
  • FIG. 1 mean plasma concentration of the CPBI compound fluralaner administered orally to dogs.
  • FIG. 2 mean plasma concentration of the isoxaoline compounds afoxolaner and -[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide administered orally to dogs.
  • the present invention relates to the formulation of a solid oral dosage form (sometimes referred to as solid pharmaceutical composition or formulation) containing an isoxazoline compound of Formula (I) (as described below), that provides significantly improved bioavailability of such isoxazoline compound after administration to an animal.
  • a solid oral dosage form sometimes referred to as solid pharmaceutical composition or formulation
  • an isoxazoline compound of Formula (I) as described below
  • the isoxazoline compound of Formula (I) is dissolved in a solvent. This drug solution is then adsorbed onto a solid carrier which is incorporated into a traditional solid oral dosage form. Utilizing pre-dissolved isoxazoline compounds of Formula (I) in the formulation significantly improves the bioavailability of the active drug substance compared to traditional solid oral dosage forms containing the active drug substance incorporated as a solid.
  • DMAC dimethylacetamide
  • This formulation approach provides unexpectedly significant improvement in bioavailability, enabling a significantly lower dosage required to achieve similar or superior pharmakokinetic profiles. Hence, similar blood levels can be achieved that lead to similar effectiveness to control parasites but with a reduced dosage of the isoxazoline compound.
  • the solid oral dosage form according to the invention comprises an isoxazoline compound of the Formula (I)
  • T is selected from
  • Preferred compounds of Formula (I) are:
  • a more preferred compound has the Formula (II),
  • R 3 is H and R 4 is —CH 2 —C(O)—NH—CH 2 —CF 3 , —CH 2 —C(O)—NH—CH 2 —CH 3 , —CH 2 —CH 2 —CF 3 or —CH 2 —CF 3 .
  • the compound of Formula (I) is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3-USAN fluralaner).
  • the compound of Formula (I) is (Z)-4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
  • the compound of Formula (I) is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CAS RN 1164267-94-0) that was disclosed in WO2009/0080250.
  • the compound of Formula (I) is 4-[5-[3-Chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (CAS RN 1093861-60-9, USAN-afoxolaner) that was disclosed in WO2007/079162-.
  • the compound of Formula (I) is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide (CAS RN 1231754-09-8) that was disclosed in WO2010/070068.
  • Especially preferred compounds of Formula (II) are:
  • Isoxazoline compounds are known in the art and these compounds and their use as parasiticide are described, for example, in US patent application No. US 2007/0066617, and International Patent applications WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO2009/080250, WO 2010/070068, WO 2010/079077, WO 2011/075591 and WO 2011/124998, the disclosures of which, as well as the references cited herein, are incorporated by reference.
  • This class of compounds is known to possess excellent activity against ectoparasites such as ticks and fleas.
  • the isoxazoline compounds may exist in various isomeric forms.
  • a reference to an isoxazoline compound always includes all possible isomeric forms of such compound.
  • a compound structure that does not indicate a particular conformation is intended to encompass compositions of all the possible conformational isomers of the compound, as well as compositions comprising fewer than all the possible conformational isomers.
  • the compound is a chiral compound. In some embodiments, the compound is a non-chiral compound.
  • Isoxazoline compounds of Formula (I) can be prepared according to one or other of the processes described e.g. in Patent Applications US 2007/0066617, WO 2007/079162, WO 2009/002809, WO 2009/080250, WO 2010/070068, WO 2010/079077, 2011/075591 and WO 2011/124998 or any other process coming within the competence of a person skilled in the art who is an expert in chemical synthesis.
  • a person skilled in the art is regarded as having at his disposal, inter alia, the entire contents of “Chemical Abstracts” and of the documents which are cited therein.
  • formulations according to the invention are effective for long durations of time in the treatment of ectoparasites of mammals and, in particular, of fleas and ticks in small mammals such as dogs and cats.
  • the amount of the isoxazoline compound of Formula (I) in the formulation may be in the range of 1-15% w/w. In an alternative embodiment the amount of such compound may be in the range of 2.0-7.5% w/w. The preferred range is 3.0-4.5% w/w.
  • the composition comprises a solid carrier, e.g. microcrystalline cellulose, colloidal silicone dioxide, polyvinyl pyrrolidone or other solid carrier excipient with appropriate characteristic behaviours.
  • a solid carrier e.g. microcrystalline cellulose, colloidal silicone dioxide, polyvinyl pyrrolidone or other solid carrier excipient with appropriate characteristic behaviours.
  • the solid carrier is microcrystalline cellulose (10.0-50.0% w/w, preferred 15.0-25.0% w/w).
  • one preferred solvent is a pyrrolidone solvent, especially 2-pyrrolidone.
  • pyrrolidone solvents such as N-methylpyrrolidone can be used.
  • dimethyl acetamide Another preferred solvent is dimethyl acetamide (DMAC).
  • DMAC dimethyl acetamide
  • Alternative solvents for use in the current invention dimethyl sulfoxide, dimethyl formamide, diethylene glycol monoethyl ether, ethyl lactate, ethylene monomethyl ether, glycofurol, N,N-diethyl-m-toluamide (DEET) or other solvent with suitable solubility for the compound of Formula (I). Solvent combinations may also be utilized in the formulation according to the invention. The preferred range of such other solvents is 2.0-35.0% w/w.
  • the amount of the pyrrolidone solvent, especially 2-pyrrolidone in the formulation may be in the range of 2.5-30.0% w/w.
  • the preferred range is 7.0-12.0% w/w.
  • the preferred range of other dimethyl acetamide is 2.0-35.0% w/w.
  • the solid oral dosage form is a soft chew.
  • the solid oral dosage form is a conventional (hard) tablet.
  • Such tablet can include a coating or can include excipients for extended release that are known in the art.
  • granules for oral administration or capsules are employed.
  • Soft chew or “Soft chewable veterinary pharmaceutical product” is intended to mean a product which is solid at room temperature and that is soft to chew and which is functionally chewy because the product has some plastic texture during the process of mastication in the mouth. Such soft chews have a softness that is similar to a cooked ground meat patty.
  • the forming agent is important for the texture of the soft chew and the possibility to form single soft chews from the dough that stay intact and separate.
  • Forming agents are agents providing texture to the soft chew product, like for example polyethylene glycol (PEG), microcrystalline wax, cetyl alcohol or polyvinylpyrrolidone (PVP).
  • the forming agent is polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • different molecular weight PEG may be utilized.
  • PEG 8000 is utilized. However, the PEG chosen is a matter of choice and the molecular weight may be higher or lower than 8000, but preferably higher than 600. Alternatively, PEG 3500 might be used.
  • the forming agent comprises about 3.0% to about 35% w/w of the pharmaceutical composition. In an alternate embodiment, a forming agent comprises about 4.5% to about 30% w/w % of the pharmaceutical composition. In an alternate embodiment, a forming agent comprises about 10% to about 20% w/w of the pharmaceutical composition. In case the forming agent is polyvinylpyrrolidone e.g. 2, 4, 5, 6 or 9% w/w are present in the soft chew.
  • a preferred formulation for the solid oral pharmaceutical composition includes:
  • the amount of glycerol in the formulation may range from 0-12.0% with the preferred range of 0.5-10.0%.
  • Soybean oil amounts may range from 5.0-25.0% with the preferred range of 10.0-22.0%. Desired ranges of the other excipients include sodium starch glycolate (2.0-15.0%), flavor (5-25%), sodium lauryl sulfate (0.05-5.0%), sodium pamoate (0.01-5.0%), aspartame (0.01-2.0%), and magnesium stearate (0.01-2.0%).
  • the formulation according to the current invention conventionally further comprise physiologically acceptable formulation excipients known in the art e.g. as described in “Gennaro, Remington: The Science and Practice of Pharmacy” (20th Edition, 2000) incorporated by reference herein. All such ingredients, carriers and excipients must be substantially pharmaceutically or veterinary pure and non-toxic in the amounts employed and must be compatible with the pharmaceutically active ingredients.
  • excipients that can be present in the formulation are e.g. one or more fillers, one or more flavours, or sugar components, surfactants, stabilizers, flow agents, disintegration agents, preservatives and/or lubricating agents.
  • This invention is also directed to formulations as described above with combinations comprising more than one pharmaceutically active ingredient, e.g. in addition to the compound of Formula (I) another compound of Formula (I) or a pharmaceutically active ingredient with a different structure.
  • Preferred combinations comprising active ingredients selected from the group consisting of isoxazoline compounds of Formula (I) or (II) and avermectins and milbemycins.
  • the formulation, especially soft chew comprises a combination of an isoxazoline compound of Formula (I), especially fluralaner or afoxolaner, with ivermectin.
  • the soft chew comprises a combination of an isoxazoline compound of Formula (I), especially fluralaner por afoxolaner, with milbemycin or with moxidectin.
  • AGRs or IGRs insect or acarid growth regulators
  • fenoxycarb e.g. fenoxycarb, lufenuron, diflubenzuron, novaluron, triflumuron, fluazuron, cyromazine, methoprene, pyriproxyfen etc.
  • fenoxycarb e.g. fenoxycarb, lufenuron, diflubenzuron, novaluron, triflumuron, fluazuron, cyromazine, methoprene, pyriproxyfen etc.
  • the inventors discovered that oral solid dosage forms of isoxazoline compounds of Formula (I) as described above, especially of fluralaner, afoxoloaner can be produced that result in a higher bioavailability of the isoxazoline compound after administration to animals.
  • the isoxazoline compound of Formula (I) is first dissolved in a suitable solvent (e.g. 2-pyrol or DMAC) and then adhered to a solid carrier (e.g. microcrystalline cellulose).
  • a suitable solvent e.g. 2-pyrol or DMAC
  • a solid carrier e.g. microcrystalline cellulose
  • a general method for preparing a solid oral dosage form, such as a soft chewable tablet formulation comprises the steps of:
  • the tablets may be formed from the final bulk mass utilizing a forming machine.
  • the tablets may be formed by other means known in the art.
  • the tablets may be formed by hand.
  • the product of the invention is intended for use for controlling a parasitic insect-, acarid and/or helminth, especially parasitic insect and/or acarid infestation.
  • controlling a parasitic insect- and/or acarid infestation refers to preventing, reducing or eliminating an infestation by such parasites on animals preferably by killing the insects and/or acarids or nematode parasites within hours or days.
  • parasitic insect- and acarid refers to ectoparasites e.g. insect and acarine pests that commonly infest or infect animals.
  • ectoparasites include the egg, larval, pupal, nymphal and adult stages of lice, fleas, mosquitoes, mites, ticks, and biting or nuisance fly species. Especially important are fleas and ticks, especially their adult stages.
  • invertebrate parasitic pests controlled by administering the solid oral formulation of this invention to an animal to be protected include ectoparasites (arthropods, acarines, etc) and endoparasites (helminths, e.g., nematodes, trematodes, cestodes, acanthocephalans, etc.).
  • ectoparasites arthropods, acarines, etc
  • endoparasites helminths, e.g., nematodes, trematodes, cestodes, acanthocephalans, etc.
  • the formulations of this invention are effective against ectoparasites including: flies such as Haematobia ( Lyperosia ) irritans (horn fly), Stomoxys calcitrans (stable fly), Simulium spp. (blackfly), Glossina spp. (tsetse flies), Hydrotaea irritans (head fly), Musca autumnalis (face fly), Musca domestica (house fly), Morellia simplex (sweat fly), Tabanus spp. (horse fly), Hypoderma bovis, Hypoderma lineatum, Lucilia sericata, Lucilia cuprina (green blowfly), Calliphora spp.
  • flies such as Haematobia ( Lyperosia ) irritans (horn fly), Stomoxys calcitrans (stable fly), Simulium spp. (blackfly), Glossina spp. (tsetse flies),
  • cyanotis ear mites
  • ticks such as Ixodes spp., Boophilus spp., Rhipicephalus spp., Amblyomma spp., Dermacentor spp., Hyalomma spp. and Haemaphysalis spp.
  • fleas such as Ctenocephalides felis (cat flea) and Ctenocephalides canis (dog flea).
  • the formulations according to the invention will contain an effective amount of the isoxazoline compounds of Formula (I) as defined above, meaning a non-toxic but sufficient amount to provide the desired control effect.
  • an appropriate “effective” amount in any individual case. Such an amount will depend on the age, condition, weight and type of the target animal.
  • the solid oral dosage forms may be formulated to contain an amount of the isoxazoline compound of Formula (I) that is adjusted to animals in a specific weight range.
  • the animals may receive a dosage of the solid oral formulation according to the invention every 2, 3, 4, 5 or 6 months or receives a monthly, weekly or daily dosage.
  • the treatment can, for example, be continuing or seasonal. The time period between treatments depends upon factors such as the parasite(s) being treated, the degree of infestation, the type of mammal or bird and the environment where it resides. It is well within the skill level of the practitioner to determine a specific administration period for a particular situation.
  • the solid oral formulations of the present invention are especially suitable for combating parasites that infest mammals (including humans).
  • Mammalian subjects include primates (e.g., monkeys), bovine (e.g., cattle or dairy cows), porcine (e.g., hogs or pigs), ovine (e.g., goats or sheep), equine (e.g., horses), canine (e.g., dogs), feline (e.g., house cats), camels, deer, donkeys, buffalos, antelopes, rabbits, and rodents (e.g., guinea pigs, squirrels, rats, mice, gerbils, and hamsters).
  • the animals to be protected are domesticated dogs (i.e. Canis lupus familiaris ) and domestic house cats (i.e. Felis catus ).
  • the solid oral formulation of an isoxazoline of Formula (I) is administered to treat parasitoses of an animal (or make a medicament to treat parasitoses of an animal).
  • parasitoses includes pathologic conditions and diseases associated with or caused by one or more ectoparasites directly, such as, for example, anemia and flea allergy dermatitis. It also includes pathologic conditions or diseases associated with caused by one or more vector-transmitted pathogens, such as, for example, Lyme disease, Ehrlichiosis (particularly Canine Ehrlichiosis), and Rocky Mountain spotted fever from vector ticks.
  • This invention also relates to treatment methods wherein at least an ancillary goal of controlling ectoparasites in and/or on an animal is to control an ectoparasitic infestation in an environment that is occupied (periodically or continuously) by the animal.
  • the animal is a companion animal (e.g., a cat or dog).
  • the environment may be, for example, a house or other shelter; a room; a pen, a stall, or other confinement means; bedding; etc.
  • kits that are, for example, suitable for use in performing the treatment methods described above.
  • a kit will comprise an oral solid formulation according to the invention comprising a therapeutically effective amount of a isoxazoline of Formula (I), and an additional component(s).
  • the additional component(s) may be, for example, one or more of the following: a diagnostic tool, instructions for administering the composition, an apparatus for administering the composition, a container comprising an excipient or other active ingredient to be mixed or administered in combination with the composition, or a memory aid (e.g., a stamp to adhere to a calendar to remind an animal owner of a time to administer a subsequent dose of the composition).
  • w/w designates weight/weight
  • w/v designates weight/volume
  • mg/kg designates milligrams per kilogram of body weight.
  • % w/w represents the percentage by weight of an ingredient in the recipe of the product.
  • Dimethylacetamide is a good solvent for the active (A-1443) with a solubility of 791.5 mg/mL.
  • DMAC Dimethylacetamide
  • This formulation approach provides significant improvement in bioavailability, enabling a significantly lower dosage required to achieve similar to superior pharmacokinetic profiles.
  • the objective of this study is to compare the blood plasma pharmacokinetic profile of three different isoxazoline compounds in two different chewable formulations after a single oral (PO) administration of in dogs.
  • the following compounds were formulated according to the invention. Specifically, the isoxazoline compound was first dissolved in a solvent, i.e. 2-pyrrolidone. This drug solution was then adsorbed onto the solid carrier, i.e. microcrystalline cellulose, which was incorporated into a solid oral dosage form as described in the specification with excipients as described in Table 3.
  • a solvent i.e. 2-pyrrolidone.
  • This drug solution was then adsorbed onto the solid carrier, i.e. microcrystalline cellulose, which was incorporated into a solid oral dosage form as described in the specification with excipients as described in Table 3.
  • Comparative example formulation ID No. 13-009, 13-011 and 13-013 contain the active drug substance incorporated as a solid that was manufactured as described in general in the specification without prior pre-dissolving the active ingredient and adsorption to the solid carrier.
  • test compounds were administered orally to four beagle dogs per dose group for a total of twenty-four dogs.
  • Each animal was administered the tablet or chew by placing it in the back of the oral cavity over the tongue to initiate swallowing.
  • Individual blood samples (approximately 4.5 mL per sample) were taken via jugular venipuncture into sodium-citrate tubes from all dogs for drug analysis. Blood samples were collected at the following time points: pretreatment (within 2 h prior to dosing) and approximately 1, 2, 4, 6, 8, 24, 48, 72 hours after dosing ( ⁇ 15 min). A final blood sample was taken from each dog on Day 7 ( ⁇ 2 h after the time of dosing on Day 0).
  • a solid pharmaceutical composition according to the invention with the following excipients was prepared.
  • Excipient Composition (% w/w) Fluralaner 4.27% 2-pyrrolidone 10.19% microcrystalline cellulose 24.27% sodium starch glycolate 4.95% flavor 14.56% sodium lauryl sulfate 3.40% sodium pamoate 2.43% aspartame 0.49% magnesium stearate 0.49% glycerol 2.91% soybean oil 16.75% Polyethylene Glycol 8000 15.29%
  • Dogs were randomly assigned to 4 treatment groups of 8 animals each, and one untreated control group of 8 animals.
  • the dogs in the treatment groups were treated with the composition as described above on Day Zero as shown in Table 6:
  • the dogs were infested on Day ⁇ 2 with approximately 50 adult unfed ticks ( R. sanguineus ) and on Day 28 and 56. Ticks were counted approximately 48 h post infestation and on Days 30 and 58 (approximately 48 hour after each post-treatment re-infestation) to evaluate the acaricidal activity in the treated groups.

Abstract

A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.

Description

    BACKGROUND OF THE INVENTION
  • A number of parasites can infest or infect domestic animals especially also companion animals such as cats and dogs. These pests and parasites are of great nuisance to both the animals and their owners.
  • Isoxazoline compounds are known in the art and these compounds and their use as antiparasitic are described, for example, in US patent application US 2007/0066617, and International Patent applications WO 2005/085216, WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO 2009/080250, WO 2010/070068 and WO 2010/079077, the disclosures of which, as well as the references cited herein, are incorporated by reference.
  • This class of compounds is known to possess excellent activity against ectoparasites, i.e. parasitic insect and acarids, such as ticks and fleas and endoparasites such as nematodes.
  • Examples of isoxazoline compounds are carbamoyl benzamide phenyl isoxazoline (CBPI) compounds. A specific example of a CBPI compound is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN [864731-61-3])—USAN fluralaner.
  • Figure US20230320981A1-20231012-C00001
  • The CBPI compound fluralaner is disclosed in patent application WO 2005/085216.
  • As these isoxazoline compounds have been originally investigated for their use in the agricultural area it is necessary to identify specific formulations that allow their veterinary use, i.e. safe administration to control parasites in animals effectively.
  • One known and convenient way of administering an ectoparasiticide compound to an animal is oral administration, e.g. as solid oral formulation such as tablets or soft chews that have a high bioavailability to allow the control of parasites with a low dosage of the ectoparasiticide compound orally administered to the animal.
    • SUMMARY OF THE INVENTION
  • In one aspect the current invention is directed to a solid oral pharmaceutical composition comprising an effective amount of at least one isoxazoline compound of the Formula (I)
  • Figure US20230320981A1-20231012-C00002
  • wherein
      • R1=halogen, CF3, OCF3, CN,
      • n=integer from 0 to 3, preferably 1, 2 or 3,
      • R2=C1-C3-haloalkyl, preferably CF3 or CF2Cl,
      • T=5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
      • Y=methyl, halomethyl, halogen, CN, NO2, NH2—C═S, or two adjacent radicals Y form together a chain, especially a three or four membered chain;
      • Q=X—NR3R4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals;
      • X=CH2, CH(CH3), CH(CN), CO, CS,
      • R3=hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
  • Figure US20230320981A1-20231012-C00003
    Figure US20230320981A1-20231012-C00004
      • wherein ZA=hydrogen, halogen, cyano, halomethyl (CF3);
      • R4=hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;
      • or R3 and R4 together form a substituent selected from the group consisting of:
  • Figure US20230320981A1-20231012-C00005
      • or a salt or solvate thereof, a solid carrier and a solvent, wherein the solvent is selected from 2-pyrrolidone, dimethylacetamide or mixtures thereof.
  • In a preferred embodiment the solid oral pharmaceutical composition is a soft chewable veterinary pharmaceutical composition for oral administration.
  • In a preferred embodiment the solid carrier is microcrystalline cellulose.
  • In one embodiment the composition further comprises pamoic acid or a pharmaceutically acceptable salt thereof.
  • In one embodiment the isoxazoline compound is fluralaner.
  • In one embodiment the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N—[(Z)-(methoxyimino)methyl]-2-methyl-benzamide.
  • In one embodiment the isoxazoline compound is afoxolaner.
  • In one embodiment the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide.
  • In one embodiment the isoxazoline compound is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide.
  • In one embodiment the solid oral pharmaceutical composition comprises an additional pharmaceutically active compound.
  • In one embodiment the additional pharmaceutically active compound is a macrocyclic lactone selected from the group of ivermectin, milbemycin, and moxidectin.
  • In one embodiment the solid oral pharmaceutical composition comprises an isoxazoline compound of Formula (I) or a salt or solvate thereof, 2-pyrrolidone, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, sodium pamoate, magnesium stearate, aspartame, glycerol, soybean oil, and polyethylene glycol
  • In another embodiment the solid oral pharmaceutical composition comprises an isoxazoline compound of Formula (I) or a salt or solvate thereof, dimethyl acetamide, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, sodium pamoate, magnesium stearate, aspartame, glycerol, soybean oil, and polyethylene glycol.
  • Another aspect of the invention is a method of preparing a solid pharmaceutical composition comprising dissolving the isoxazoline compound as above in the solvent and then adsorbing the resulting solution on to the solid carrier excipient.
  • In one embodiment of this method the solid carrier is microcrystalline cellulose.
  • In another embodiment of this method the solvent is 2-pyrrolidone or dimethyl acetamide.
  • Another aspect of the current invention is a method of controlling parasite infestation in an animal comprising administering to the animal a therapeutically effective amount of the composition as described above.
  • Another aspect of the current invention is a solid oral pharmaceutical composition comprising an isoxazoline compound of Formula (I) or a salt or solvate thereof, and 2-pyrrolidone.
  • In one embodiment the isoxazoline compound is fluralaner.
  • In one embodiment the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N—[(Z)-(methoxyimino)methyl]-2-methyl-benzamide.
  • In one embodiment the isoxazoline compound is afoxolaner.
  • In one embodiment the isoxazoline compound is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide.
  • In one embodiment the isoxazoline compound is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide.
  • In one embodiment the solid oral pharmaceutical composition is a soft chewable veterinary pharmaceutical composition for oral administration.
  • Another aspect of the current invention is a method of controlling parasite infestation in an animal comprising administering to the animal a therapeutically effective amount of the composition as described above.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 —mean plasma concentration of the CPBI compound fluralaner administered orally to dogs.
  • FIG. 2 —mean plasma concentration of the isoxaoline compounds afoxolaner and -[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide administered orally to dogs.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to the formulation of a solid oral dosage form (sometimes referred to as solid pharmaceutical composition or formulation) containing an isoxazoline compound of Formula (I) (as described below), that provides significantly improved bioavailability of such isoxazoline compound after administration to an animal.
  • Specifically, in this formulation the isoxazoline compound of Formula (I) is dissolved in a solvent. This drug solution is then adsorbed onto a solid carrier which is incorporated into a traditional solid oral dosage form. Utilizing pre-dissolved isoxazoline compounds of Formula (I) in the formulation significantly improves the bioavailability of the active drug substance compared to traditional solid oral dosage forms containing the active drug substance incorporated as a solid.
  • As indicated in the example the inventors discovered, that with dimethylacetamide (DMAC) as solvent for isoxazoline compounds in a solid oral dosage form similar pharmacokinetic profiles were obtained when it was s dosed at a lower dose compared to dosage forms with the active incorporated in higher dosage as a solid.
  • When 2-pyrrolidone (2-pyrol) was utilized as the solvent in the formulation, significantly higher plasma levels were observed compared to the control, even with the formulation comprising an isoxazoline compound dosed at a lower dose.
  • This formulation approach provides unexpectedly significant improvement in bioavailability, enabling a significantly lower dosage required to achieve similar or superior pharmakokinetic profiles. Hence, similar blood levels can be achieved that lead to similar effectiveness to control parasites but with a reduced dosage of the isoxazoline compound.
  • The solid oral dosage form according to the invention comprises an isoxazoline compound of the Formula (I)
  • Figure US20230320981A1-20231012-C00006
  • wherein
      • R1=halogen, CF3, OCF3, CN,
      • n=integer from 0 to 3, preferably 1, 2 or 3,
      • R2=C1-C3-haloalkyl, preferably CF3 or CF2Cl,
      • T=5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
      • Y=methyl, halomethyl, halogen, CN, NO2, NH2—C═S, or two adjacent radicals Y form together a chain CH—CH═CH—CH, N—CH═CH—CH, CH—N═CH—CH, CH—CH═N—CH, or CH—CH═CH—N, HC═HC—CH, CH—CH═CH, CH═CH—N, N—CH═CH;
      • Q=X—NR3R4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals ZA, ZB ZD;
      • X=CH2, CH(CH3), CH(CN), CO, CS,
      • R3=hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
  • Figure US20230320981A1-20231012-C00007
    Figure US20230320981A1-20231012-C00008
      • R4=hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl; or
      • R3 and R4 together form a substituent selected from the group consisting of:
  • Figure US20230320981A1-20231012-C00009
      • wherein ZA=hydrogen, halogen, cyano, halomethyl (CF3);
      • or a salt or solvate thereof, a solid carrier and a solvent, wherein the solvent is selected from 2-pyrrolidone, dimethylacetamide or mixtures thereof.
  • In one preferred embodiment in Formula (I) T is selected from
  • Figure US20230320981A1-20231012-C00010
    Figure US20230320981A1-20231012-C00011
    Figure US20230320981A1-20231012-C00012
      • wherein in T-1, T-3 and T-4 the radical Y is hydrogen, halogen, methyl, halomethyl, ethyl, haloethyl.
  • In a preferred embodiment in Formula (I) Q is selected from
  • Figure US20230320981A1-20231012-C00013
      • Wherein R3, R4, X and ZA are as defined above.
      • ZB=
  • Figure US20230320981A1-20231012-C00014
    Figure US20230320981A1-20231012-C00015
      • ZD=
  • Figure US20230320981A1-20231012-C00016
  • Preferred compounds of Formula (I) are:
  • (R1)n R2 R3 R4 T Y Q Z X
    3-Cl, 5Cl CF3 CH2CF3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2CH3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2CH2OCH3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CH3 H T-2 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CH3 H T-2 — Q-1 — C(O)
    3-CF3, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-CF3, 5-Cl CF3 CH2C(O)NHCH2CH3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 — T-2 — Q-6 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-7 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-5 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-2 ZD-1
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CC H T-3 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CN H T-3 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CH3 H T-3 CH3 Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CH3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-Cl, 5-Cl CF3 CH2C(O)NHCH2CH3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-F, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-F, 5-Cl CF3 CH2C(O)NHCH2CH3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-20 — Q-1 — C(O)
    3-Cl, 5-Cl CF3 CH2C(O)NHCH2CH3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 CH3 T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CH3 CH3 T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CH3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-21 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CH3 H T-21 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-21 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CH3 H T-21 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2CH2SCH3 H T-21 — Q-1 — C(O)
    3-Cl, 4-Cl, 5-Cl CF3 C(O)CH3 H T-22 F Q-1 — CH2
    3-Cl, 4-Cl, 5-Cl CF3 C(O)CH(CH3)2 H T-22 F Q-1 — CH2
    3-Cl, 4-Cl, 5-Cl CF3 C(O)-cyclo-propyl H T-22 F Q-1 — CH2
    3-Cl, 4-F, 5-Cl CF3 C(O)CH3 H T-22 F Q-1 — CH2
    3-Cl, 4-Cl, 5-Cl CF3 C(O)CH2CH3 H T-22 F Q-1 — CH2
    3-Cl, 4-F, 5-Cl CF3 C(O)CH3 H T-22 Cl Q-1 — CH2
    3-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-1 CH3 Q-1 — C(O)
    3-Cl, 5-Cl CF3 CH2C(O)NHCH2CH3 H T-1 CH3 Q-1 — C(O)
    3-Cl, 5-Cl CF3 R3-1 (Z) H T-1 CH3 Q-1 — C(O)
    3-Cl, 5-Cl CF3 R3-1 (E) H T-1 CH3 Q-1 — C(O)
  • Especially preferred compounds of Formula (I) are
  • (R1)n R2 R3 R4 T Y Q Z X
    3-Cl, 5Cl CF3 CH2CF3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2CH3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2CH2OCH3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-CF3, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 — T-2 — Q-6 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-7 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-5 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-2 ZD-1
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CC H T-3 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CN H T-3 CH3 Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-F, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 CH3 T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-21 — Q-1 — C(O)
    3-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-21 — Q-1 — C(O)
    3-Cl, 5-Cl CF3 CH2CH2SCH3 H T-21 — Q-1 — C(O)
    3-Cl, 4-Cl, 5-Cl CF3 C(O)CH3 H T-22 F Q-1 — CH2
    3-Cl, 4-Cl, 5-Cl CF3 C(O)CH(CH3)2 H T-22 F Q-1 — CH2
    3-Cl, 4-Cl, 5-Cl CF3 C(O)-cyclo-propyl H T-22 F Q-1 — CH2
    3-Cl, 4-F, 5-Cl CF3 C(O)CH3 H T-22 F Q-1 — CH2
    3-Cl, 4-Cl, 5-Cl CF3 C(O)CH2CH3 H T-22 F Q-1 — CH2
    3-Cl, 4-F, 5-Cl CF3 C(O)CH3 H T-22 Cl Q-1 — CH2
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-1 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 R3-1 (Z) H T-1 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 R3-1 (E) H T-1 CH3 Q-1 — C(O)
  • A more preferred compound has the Formula (II),
  • Figure US20230320981A1-20231012-C00017
      • Wherein
      • R1a, R1b, R1c are independently from each other hydrogen, Cl or CF3, preferably R1a and R1c are Cl or CF3 and R1b is hydrogen,
      • T is
  • Figure US20230320981A1-20231012-C00018
      • wherein Y is methyl, bromine, Cl, F, CN or C(S)NH2, and
      • Q is as described above.
  • In another preferred embodiment in R3 is H and R4 is —CH2—C(O)—NH—CH2—CF3, —CH2—C(O)—NH—CH2—CH3, —CH2—CH2—CF3 or —CH2—CF3.
  • In one embodiment the compound of Formula (I) is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN 864731-61-3-USAN fluralaner).
  • In another embodiment the compound of Formula (I) is (Z)-4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
  • In another embodiment the compound of Formula (I) is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CAS RN 1164267-94-0) that was disclosed in WO2009/0080250.
  • In another embodiment the compound of Formula (I) is 4-[5-[3-Chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide (CAS RN 1093861-60-9, USAN-afoxolaner) that was disclosed in WO2007/079162-.
  • In another embodiment the compound of Formula (I) is 5-[5-(3,5-Dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide (CAS RN 1231754-09-8) that was disclosed in WO2010/070068.
  • An especially preferred compound is
  • Figure US20230320981A1-20231012-C00019
  • Especially preferred compounds of Formula (II) are:
  • (R1)n R2 R3 R4 T Y Q Z X
    3-Cl, 5Cl CF3 CH2CF3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-CF3, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-2 — Q-1 — C(O)
    3-Cl, 5Cl CF3 — T-2 — Q-6 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-7 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-5 ZB-7
    3-Cl, 5Cl CF3 — — T-2 — Q-2 ZD-1
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-Cl, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 4-F, 5-Cl CF3 CH2C(O)NHCH2CF3 H T-3 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 CH3 T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-20 — Q-1 — C(O)
    3-CF3, 5-CF3 CF3 CH2C(O)NHCH2CF3 H T-21 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-21 — Q-1 — C(O)
    3-Cl, 5Cl CF3 CH2C(O)NHCH2CF3 H T-1 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 R3-1 (Z) H T-1 CH3 Q-1 — C(O)
    3-Cl, 5Cl CF3 R3-1 (E) H T-1 CH3 Q-1 — C(O)
  • Isoxazoline compounds are known in the art and these compounds and their use as parasiticide are described, for example, in US patent application No. US 2007/0066617, and International Patent applications WO 2007/079162, WO 2009/002809, WO 2009/024541, WO 2009/003075, WO2009/080250, WO 2010/070068, WO 2010/079077, WO 2011/075591 and WO 2011/124998, the disclosures of which, as well as the references cited herein, are incorporated by reference. This class of compounds is known to possess excellent activity against ectoparasites such as ticks and fleas.
  • The isoxazoline compounds may exist in various isomeric forms. A reference to an isoxazoline compound always includes all possible isomeric forms of such compound. Unless otherwise stated, a compound structure that does not indicate a particular conformation is intended to encompass compositions of all the possible conformational isomers of the compound, as well as compositions comprising fewer than all the possible conformational isomers. In some embodiments, the compound is a chiral compound. In some embodiments, the compound is a non-chiral compound.
  • Isoxazoline compounds of Formula (I) can be prepared according to one or other of the processes described e.g. in Patent Applications US 2007/0066617, WO 2007/079162, WO 2009/002809, WO 2009/080250, WO 2010/070068, WO 2010/079077, 2011/075591 and WO 2011/124998 or any other process coming within the competence of a person skilled in the art who is an expert in chemical synthesis. For the chemical preparation of the products of the invention, a person skilled in the art is regarded as having at his disposal, inter alia, the entire contents of “Chemical Abstracts” and of the documents which are cited therein.
  • The formulations according to the invention are effective for long durations of time in the treatment of ectoparasites of mammals and, in particular, of fleas and ticks in small mammals such as dogs and cats.
  • The amount of the isoxazoline compound of Formula (I) in the formulation may be in the range of 1-15% w/w. In an alternative embodiment the amount of such compound may be in the range of 2.0-7.5% w/w. The preferred range is 3.0-4.5% w/w.
  • In one embodiment, the composition comprises a solid carrier, e.g. microcrystalline cellulose, colloidal silicone dioxide, polyvinyl pyrrolidone or other solid carrier excipient with appropriate characteristic behaviours.
  • In one embodiment the solid carrier is microcrystalline cellulose (10.0-50.0% w/w, preferred 15.0-25.0% w/w).
  • In the formulation according to the invention one preferred solvent is a pyrrolidone solvent, especially 2-pyrrolidone. Alternatively other pyrrolidone solvents such as N-methylpyrrolidone can be used.
  • Another preferred solvent is dimethyl acetamide (DMAC). The preferred range of dimethyl acetamide (DMAC) is 2.0-35.0% w/w. Alternative solvents for use in the current invention dimethyl sulfoxide, dimethyl formamide, diethylene glycol monoethyl ether, ethyl lactate, ethylene monomethyl ether, glycofurol, N,N-diethyl-m-toluamide (DEET) or other solvent with suitable solubility for the compound of Formula (I). Solvent combinations may also be utilized in the formulation according to the invention. The preferred range of such other solvents is 2.0-35.0% w/w.
  • The amount of the pyrrolidone solvent, especially 2-pyrrolidone in the formulation may be in the range of 2.5-30.0% w/w. The preferred range is 7.0-12.0% w/w. The preferred range of other dimethyl acetamide is 2.0-35.0% w/w.
  • In one embodiment, the solid oral dosage form is a soft chew. In another embodiment, the solid oral dosage form is a conventional (hard) tablet. Such tablet can include a coating or can include excipients for extended release that are known in the art. In yet another embodiment, granules for oral administration or capsules are employed.
  • “Soft chew” or “Soft chewable veterinary pharmaceutical product” is intended to mean a product which is solid at room temperature and that is soft to chew and which is functionally chewy because the product has some plastic texture during the process of mastication in the mouth. Such soft chews have a softness that is similar to a cooked ground meat patty.
  • In soft chew formulations the forming agent is important for the texture of the soft chew and the possibility to form single soft chews from the dough that stay intact and separate. Forming agents are agents providing texture to the soft chew product, like for example polyethylene glycol (PEG), microcrystalline wax, cetyl alcohol or polyvinylpyrrolidone (PVP). In an embodiment, the forming agent is polyethylene glycol (PEG). Moreover, depending upon the desired consistency of the soft chew, different molecular weight PEG may be utilized. In an embodiment, PEG 8000 is utilized. However, the PEG chosen is a matter of choice and the molecular weight may be higher or lower than 8000, but preferably higher than 600. Alternatively, PEG 3500 might be used.
  • In an embodiment, the forming agent comprises about 3.0% to about 35% w/w of the pharmaceutical composition. In an alternate embodiment, a forming agent comprises about 4.5% to about 30% w/w % of the pharmaceutical composition. In an alternate embodiment, a forming agent comprises about 10% to about 20% w/w of the pharmaceutical composition. In case the forming agent is polyvinylpyrrolidone e.g. 2, 4, 5, 6 or 9% w/w are present in the soft chew.
  • A preferred formulation for the solid oral pharmaceutical composition includes:
      • 4.4% w/w compound of Formula (I), especially fluralaner
      • 10.5% w/w 2-pyrrolidone
      • 25.0% w/w microcrystalline cellulose
      • 5.1% w/w sodium starch glycolate
      • 15.0% w/w flavor
      • 2.0% w/w sodium lauryl sulphate
      • 2.5% w/w sodium pamoate
      • 0.5% w/w aspartame
      • 0.5% w/w magnesium stearate
      • 1.5% w/w glycerol
      • 17.25% w/w soybean oil
      • 15.75% w/w PEG8000
  • The amount of glycerol in the formulation may range from 0-12.0% with the preferred range of 0.5-10.0%. Soybean oil amounts may range from 5.0-25.0% with the preferred range of 10.0-22.0%. Desired ranges of the other excipients include sodium starch glycolate (2.0-15.0%), flavor (5-25%), sodium lauryl sulfate (0.05-5.0%), sodium pamoate (0.01-5.0%), aspartame (0.01-2.0%), and magnesium stearate (0.01-2.0%).
  • The formulation according to the current invention conventionally further comprise physiologically acceptable formulation excipients known in the art e.g. as described in “Gennaro, Remington: The Science and Practice of Pharmacy” (20th Edition, 2000) incorporated by reference herein. All such ingredients, carriers and excipients must be substantially pharmaceutically or veterinary pure and non-toxic in the amounts employed and must be compatible with the pharmaceutically active ingredients.
  • Additional excipients that can be present in the formulation are e.g. one or more fillers, one or more flavours, or sugar components, surfactants, stabilizers, flow agents, disintegration agents, preservatives and/or lubricating agents.
  • This invention is also directed to formulations as described above with combinations comprising more than one pharmaceutically active ingredient, e.g. in addition to the compound of Formula (I) another compound of Formula (I) or a pharmaceutically active ingredient with a different structure.
  • Preferred combinations comprising active ingredients selected from the group consisting of isoxazoline compounds of Formula (I) or (II) and avermectins and milbemycins. In one embodiment the formulation, especially soft chew comprises a combination of an isoxazoline compound of Formula (I), especially fluralaner or afoxolaner, with ivermectin. In another embodiment the soft chew comprises a combination of an isoxazoline compound of Formula (I), especially fluralaner por afoxolaner, with milbemycin or with moxidectin.
  • Other combinations of the present invention can include insect or acarid growth regulators (AGRs or IGRs) such as e.g. fenoxycarb, lufenuron, diflubenzuron, novaluron, triflumuron, fluazuron, cyromazine, methoprene, pyriproxyfen etc., thereby providing both initial and sustained control of parasites (at all stages of insect development, including eggs) on the animal subject, as well as within the environment of the animal subject.
  • The inventors discovered that oral solid dosage forms of isoxazoline compounds of Formula (I) as described above, especially of fluralaner, afoxoloaner can be produced that result in a higher bioavailability of the isoxazoline compound after administration to animals. In such methods the isoxazoline compound of Formula (I) is first dissolved in a suitable solvent (e.g. 2-pyrol or DMAC) and then adhered to a solid carrier (e.g. microcrystalline cellulose). Such process can be used in general for various solid oral dosage forms such as hard tablets, granules, capsules or soft chews (soft chewable tablets).
  • A general method for preparing a solid oral dosage form, such as a soft chewable tablet formulation comprises the steps of:
      • 1. Dissolve the isoxazoline compound (e.g. fluralaner or afoxolaner) in the solvent (e.g. 2-pyrrolidone) to form a solution.
      • 2. Add the isoxazoline solution to the solid carrier (e.g. microcrystalline cellulose) and mix to form a first dry mixture.
      • 3. Add all other dry excipients to the first dry mixture and mix to form a second dry mixture.
      • 4. Add liquid ingredients, glycerol and soybean oil, to the second dry mixture. Mix to form wet mass.
      • 5. Melt a wax (e.g., polyethylene glycol 8000) and add to the wet mass. Mix well to form the final bulk mass.
      • 6. Form appropriately sized chewable tablets.
  • In an embodiment the tablets may be formed from the final bulk mass utilizing a forming machine. Alternatively, the tablets may be formed by other means known in the art. For example, the tablets may be formed by hand.
  • Methods of Using the Solid Oral Pharmaceutical Compositions
  • In one embodiment the product of the invention is intended for use for controlling a parasitic insect-, acarid and/or helminth, especially parasitic insect and/or acarid infestation. The term “controlling a parasitic insect- and/or acarid infestation” refers to preventing, reducing or eliminating an infestation by such parasites on animals preferably by killing the insects and/or acarids or nematode parasites within hours or days.
  • The term “parasitic insect- and acarid” refers to ectoparasites e.g. insect and acarine pests that commonly infest or infect animals. Examples of such ectoparasites include the egg, larval, pupal, nymphal and adult stages of lice, fleas, mosquitoes, mites, ticks, and biting or nuisance fly species. Especially important are fleas and ticks, especially their adult stages.
  • Examples of invertebrate parasitic pests controlled by administering the solid oral formulation of this invention to an animal to be protected include ectoparasites (arthropods, acarines, etc) and endoparasites (helminths, e.g., nematodes, trematodes, cestodes, acanthocephalans, etc.).
  • In particular, the formulations of this invention are effective against ectoparasites including: flies such as Haematobia (Lyperosia) irritans (horn fly), Stomoxys calcitrans (stable fly), Simulium spp. (blackfly), Glossina spp. (tsetse flies), Hydrotaea irritans (head fly), Musca autumnalis (face fly), Musca domestica (house fly), Morellia simplex (sweat fly), Tabanus spp. (horse fly), Hypoderma bovis, Hypoderma lineatum, Lucilia sericata, Lucilia cuprina (green blowfly), Calliphora spp. (blowfly), Protophormia spp., Oestrus ovis (nasal botfly), Culicoides spp. (midges), Hippobosca equine, Gastrophilus instestinalis, Gastrophilus haemorrhoidalis and Gastrophilus naslis; lice such as Bovicola (Damalinia) bovis, Bovicola equi, Haematopinus asini, Felicola subrostratus, Heterodoxus spiniger, Lignonathus setosus and Trichodectes canis; keds such as Melophagus ovinus; mites such as Psoroptes spp., Sarcoptes scabei, Chorioptes bovis, Demodex equi, Cheyletiella spp., Notoedres cati, Trombicula spp. and Otodectes cyanotis (ear mites); ticks such as Ixodes spp., Boophilus spp., Rhipicephalus spp., Amblyomma spp., Dermacentor spp., Hyalomma spp. and Haemaphysalis spp.; and fleas such as Ctenocephalides felis (cat flea) and Ctenocephalides canis (dog flea).
  • In general, the formulations according to the invention will contain an effective amount of the isoxazoline compounds of Formula (I) as defined above, meaning a non-toxic but sufficient amount to provide the desired control effect. A person skilled in the art using routine experimentation may determine an appropriate “effective” amount in any individual case. Such an amount will depend on the age, condition, weight and type of the target animal.
  • The solid oral dosage forms may be formulated to contain an amount of the isoxazoline compound of Formula (I) that is adjusted to animals in a specific weight range. The animals may receive a dosage of the solid oral formulation according to the invention every 2, 3, 4, 5 or 6 months or receives a monthly, weekly or daily dosage. The treatment can, for example, be continuing or seasonal. The time period between treatments depends upon factors such as the parasite(s) being treated, the degree of infestation, the type of mammal or bird and the environment where it resides. It is well within the skill level of the practitioner to determine a specific administration period for a particular situation.
  • The solid oral formulations of the present invention are especially suitable for combating parasites that infest mammals (including humans). Mammalian subjects include primates (e.g., monkeys), bovine (e.g., cattle or dairy cows), porcine (e.g., hogs or pigs), ovine (e.g., goats or sheep), equine (e.g., horses), canine (e.g., dogs), feline (e.g., house cats), camels, deer, donkeys, buffalos, antelopes, rabbits, and rodents (e.g., guinea pigs, squirrels, rats, mice, gerbils, and hamsters). Of particular note is the embodiment wherein the animals to be protected are domesticated dogs (i.e. Canis lupus familiaris) and domestic house cats (i.e. Felis catus).
  • In some embodiments of this invention, the solid oral formulation of an isoxazoline of Formula (I) is administered to treat parasitoses of an animal (or make a medicament to treat parasitoses of an animal). The term “parasitoses” includes pathologic conditions and diseases associated with or caused by one or more ectoparasites directly, such as, for example, anemia and flea allergy dermatitis. It also includes pathologic conditions or diseases associated with caused by one or more vector-transmitted pathogens, such as, for example, Lyme disease, Ehrlichiosis (particularly Canine Ehrlichiosis), and Rocky Mountain spotted fever from vector ticks.
  • This invention also relates to treatment methods wherein at least an ancillary goal of controlling ectoparasites in and/or on an animal is to control an ectoparasitic infestation in an environment that is occupied (periodically or continuously) by the animal. In some such embodiments, for example, the animal is a companion animal (e.g., a cat or dog). The environment may be, for example, a house or other shelter; a room; a pen, a stall, or other confinement means; bedding; etc.
  • This invention also is directed to kits that are, for example, suitable for use in performing the treatment methods described above. In general, such a kit will comprise an oral solid formulation according to the invention comprising a therapeutically effective amount of a isoxazoline of Formula (I), and an additional component(s). The additional component(s) may be, for example, one or more of the following: a diagnostic tool, instructions for administering the composition, an apparatus for administering the composition, a container comprising an excipient or other active ingredient to be mixed or administered in combination with the composition, or a memory aid (e.g., a stamp to adhere to a calendar to remind an animal owner of a time to administer a subsequent dose of the composition).
  • As used herein, the term “w/w” designates weight/weight, the term “w/v” designates weight/volume, and the term “mg/kg” designates milligrams per kilogram of body weight. As used herein, % w/w represents the percentage by weight of an ingredient in the recipe of the product.
  • The invention, having been fully described its practice, is illustrated by the examples provided below. The examples do not limit the scope of the invention, which is defined entirely by the appended claims.
    • EXAMPLES Example 1
  • An embodiment for a direct compression tablet containing two active ingredients includes:
      • 0.015% w/w ivermectin
      • 2.5% w/w fluralaner
      • 0.1% w/w citric acid
      • 0.5% w/w Cremaphor RH40
      • 4.5% w/w 2-pyrrolidone
      • 50.0% w/w microcrystalline cellulose
      • 33.735% w/w corn starch
      • 8.0% w/w flavor
      • 0.5% magnesium stearate
      • 0.1% w/w aspartame
      • 0.05% w/w red iron oxide
    Example 2
  • An embodiment for soft chewable tablets containing two active ingredients includes:
      • 0.42% w/w moxidectin
      • 1.67% w/w fluralaner
      • 0.2% w/w citric acid
      • 4.0% w/w 2-pyrol
      • 10.0% w/w microcrystalline cellulose
      • 3.0% w/w flavor
      • 0.2% w/w aspartame
      • 4.0% w/w Klucel
      • 30.51% w/w soy grits
      • 4.0% w/w propylene glycol
      • 4.0% w/w Miglyol 812
      • 8.0% w/w cetyl alcohol
      • 10.0% w/w Cremaphor RH40
      • 20.0% w/w sodium starch glycolate
    Example 3
  • Additional embodiments for the soft chewable tablets include:
      • 5.333% w/w fluralaner
      • 9.0% w/w 2-pyrrolidone
      • 11.0% w/w microcrystalline cellulose
      • 5.0% w/w Pluronic 127
      • 5.0% w/w sodium lauryl sulfate
      • 10.0% w/w flavor
      • 5.0% w/w sodium starch glycolate
      • 16.667% soy grits
      • 2.0% w/w Labrasol
      • 13.0% w/w Labrafac PG
      • 18.0% w/w PEG3350
    Example 4
      • 7.25% w/w fluralaner
      • 10.5% w/w 2-pyrrolidone
      • 22.75% microcrystalline cellulose
      • 2.0% colloidal silicone dioxide
      • 3.5% w/w Lutrol Micro 127
      • 3.5% w/w sodium lauryl sulfate
      • 15.0% w/w flavor
      • 0.5% w/w aspartame
      • 0.5% w/w magnesium stearate
      • 2.0% w/w Labrasol
      • 14.75% w/w soybean oil
      • 15.25% w/w PEG8000
    Example 5
      • 7.5% w/w fluralaner
      • 7.0% w/w dimethyl acetamide
      • 23.5% microcrystalline cellulose
      • 15.0% w/w flavor
      • 7.5% w/w sodium starch glycolate
      • 3.5% w/w sodium lauryl sulfate
      • 2.0% w/w sodium pamoate
      • 0.5% w/w magnesium stearate
      • 0.5% w/w aspartame
      • 7.0% w/w glycerol
      • 10.0% w/w soybean oil
      • 16.0% w/w PEG8000
    Example 6
      • 4.4% w/w fluralaner
      • 10.5% w/w 2-pyrrolidone
      • 25.0% microcrystalline cellulose
      • 15.0% w/w flavor
      • 5.1% w/w sodium starch glycolate
      • 3.5% w/w sodium lauryl sulfate
      • 2.5% w/w sodium pamoate
      • 0.5% w/w magnesium stearate
      • 0.5% w/w aspartame
      • 3.0% w/w glycerol
      • 14.25% w/w soybean oil
      • 15.75% w/w PEG8000
    Example 7
  • Multiple formulations were evaluated for their impact on bioavailability of Fluralaner when formulated in a soft chewable tablet.
  • The descriptions of selected formulations are listed below.
  • TABLE 1
    Control 2-Pyrol DMAC
    Excipient Formulation Formulation Formulation
    fluralaner 13.64%  4.4%  7.5%
    2-pyrrollidone 10.5%
    dimethylacetamide  7.0%
    Avicel PH102 25.0% 23.5%
    flavor 20.0% 15.0% 15.0%
    corn starch 16.06%
    sodium starch glycolate  5.1%  7.5%
    sucrose  7.0%
    sodium lauryl sulfate  2.0%  3.5%  3.5%
    sodium pamoate  2.0%  2.5%  2.0%
    magnesium stearate  0.75%  0.5%  0.5%
    aspartame  0.25%  0.5%  0.5%
    glycerol  7.5%  3.0%  7.0%
    soybean oil  12.3% 14.25%  10.0%
    Polyethylene Glycol 3350  18.5%
    Polyethylene Glycol 8000 15.75%  16.0%
  • Dimethylacetamide (DMAC) is a good solvent for the active (A-1443) with a solubility of 791.5 mg/mL. However, when utilized in this type of formulation approach, similar pharmacokinetic profiles were obtained compared to chewable tablets with the active incorporated as a solid (control). Given that the DMAC formulation was dosed at a lower dose (15 mg/kg compared to 25 mg/kg for the control), these results are improvements in dose adjusted pharmacokinetic measurements (Cmax and AUC) over the control (see Table 2 and FIG. 1 ).
  • When 2-pyrrolidone (2-pyrol) was utilized as the solvent in the formulation (solubility 775.41 mg/mL), significantly higher plasma levels were observed compared to the control, even with the formulation dosed at a lower dose (15 mg/kg compared to 25 mg/kg for the control). Dose normalized pharmacokinetic measurements (Cmax and AUC) for the 2-pyrol formulation are more than double that of the DMAC formulation and more than triple that of the control (see Table 2 and FIG. 1 ). These results were unexpected.
  • This formulation approach provides significant improvement in bioavailability, enabling a significantly lower dosage required to achieve similar to superior pharmacokinetic profiles.
  • TABLE 2
    Pharmacokinetic Control 2-Pyrol DMAC
    Parameter Formulation Formulation Formulation
    T1/2 (days) 20.3 21.6 21.3
    Tmax (hours) 40.8 55.2 48.8
    Cmax (ng/mL) 2832 5973 2511
    Dose (mg/kg) 25 15 15
    Cmax/Dose 113 398 167
    (kg * ng/mL/mg)
    AUC0-inf 1501420 3562496 1531455
    (h * ng/mL)
    AUC0-inf/Dose 60057 237500 102097
    (h * kg * ng/mL/mg)
    Bioavailability 27.8% 109.8% 47.2%
    • Example 8
  • Pharmacokinetic profile following oral administration of chewable formulations of isoxazoline compounds
  • The objective of this study is to compare the blood plasma pharmacokinetic profile of three different isoxazoline compounds in two different chewable formulations after a single oral (PO) administration of in dogs.
    • Test Formulations:
  • The following compounds were formulated according to the invention. Specifically, the isoxazoline compound was first dissolved in a solvent, i.e. 2-pyrrolidone. This drug solution was then adsorbed onto the solid carrier, i.e. microcrystalline cellulose, which was incorporated into a solid oral dosage form as described in the specification with excipients as described in Table 3. Comparative example formulation ID No. 13-009, 13-011 and 13-013 contain the active drug substance incorporated as a solid that was manufactured as described in general in the specification without prior pre-dissolving the active ingredient and adsorption to the solid carrier.
  • Figure US20230320981A1-20231012-C00020
  • TABLE 3
    Test formulations
    Excipient 13-009 13-010 13-011 13-012 13-013 13-014
    Compound A 13.64%  4.27%
    Compound B 13.64%  4.27%
    Compound C 13.64%  4.27%
    2-pyrrolidone 10.19% 10.19% 10.19%
    microcrystalline 24.27% 24.27% 24.27%
    cellulose
    sodium starch  4.95%  4.95%  4.95%
    glycolate
    flavor  20.0% 14.56%  20.0% 14.56%  20.0% 14.56%
    sucrose   7.0%   7.0%   7.0%
    corn starch 16.06% 16.06% 16.06%
    sodium lauryl   2.0%   3.4%   2.0%   3.4%   2.0%   3.4%
    sulfate
    sodium   2.0%  2.43%   2.0%  2.43%   2.0%  2.43%
    pamoate
    magnesium  0.75%  0.49%  0.75%  0.49%  0.75%  0.49%
    stearate
    aspartame  0.25%  0.49%  0.25%  0.49%  0.25%  0.49%
    glycerin   7.5%  2.91%   7.5%  2.91%   7.5%  2.91%
    soybean oil  12.3% 16.75%  12.3% 16.75%  12.3% 16.75%
    PEG 3350  18.5%  18.5%  18.5%
    PEG 8000 15.29% 15.29% 15.29%
    • Study Design
  • The test compounds were administered orally to four beagle dogs per dose group for a total of twenty-four dogs.
    • Experimental Design: Randomized Complete Block Design
  • TABLE 4
    Study Design
    Treatment No. of Formulation Compoud Dose Formulation
    ID dogs ID ID (mg/kg) Type2,3
    1 4 13-009 A 25 Control Chew
    2 4 13-010 A 10 Alternate Chew
    3 4 13-011 B 25 Control Chew
    4 4 13-012 B 10 Alternate Chew
    5 4 13-013 C 25 Control Chew
    6 4 13-014 C 10 Alternate Chew
    2Control Chew - compound is not dissolved when formulated into chew (comparative example).
    3Alternate Chew - compound is dissolved when formulated into chew
  • Each animal was administered the tablet or chew by placing it in the back of the oral cavity over the tongue to initiate swallowing.
  • Plasma was obtained from the collected blood samples and analyzed for concentrations of the test compounds. Individual blood samples (approximately 4.5 mL per sample) were taken via jugular venipuncture into sodium-citrate tubes from all dogs for drug analysis. Blood samples were collected at the following time points: pretreatment (within 2 h prior to dosing) and approximately 1, 2, 4, 6, 8, 24, 48, 72 hours after dosing (±15 min). A final blood sample was taken from each dog on Day 7 (±2 h after the time of dosing on Day 0).
    • Results:
  • When 2-pyrrolidone (2-pyrol) was utilized as the solvent in the formulation (alternate chew), similar or even higher plasma levels were observed compared to the control chew, even with the formulation dosed at a lower dose (10 mg/kg compared to 25 mg/kg for the control)—see FIG. 2 .
  • Pharmacokinetic analysis was performed on the plasma concentration data with the computer program Pharsight WinNonlin Enterprise, Version 4.0.1, or more recent update (Model 200: plasma data, extravascular input).
  • Dose normalized pharmacokinetic measurements (Cmax and AUC) for the 2-pyrol formulation (alternate chew) are much higher, in some cases more than double to five times that of the control formulation (see Table 5).
  • This formulation approach provides significant improvement in the bioavailability relative to the control formulation, enabling a significantly lower dosage required to achieve similar to superior pharmacokinetic profiles. These results were unexpected.
  • TABLE 5
    Pharmacokinetic Control Dissolved Control Dissolved Control Dissolved
    Parameter Compound A Compound B Compound C
    Dose
    25 10 25 10 25 10
    (mg/kg)
    Tmax 5.0 15.5 27.5 15.5
    (h)
    Cmax 19.2 17.1 4340 3213 1589 2538
    (ng/mL)
    Cmax/Dose 0.768 1.71 174 321 63.5 254
    (kg*ng/mL/mg)
    AUC(0-168h) ND ND 416522 334163 164332 326601
    (h*ng/mL)
    AUC(0-168h)/Dose ND ND 16661 33416 6573 32660
    (h*kg*ng/mL/mg)
    • Example 9
  • Efficacy Against Brown Dog Ticks (R. sanguineus) on Dogs
  • A solid pharmaceutical composition according to the invention with the following excipients was prepared.
  • Excipient Composition (% w/w)
    Fluralaner 4.27%
    2-pyrrolidone 10.19%
    microcrystalline cellulose 24.27%
    sodium starch glycolate 4.95%
    flavor 14.56%
    sodium lauryl sulfate 3.40%
    sodium pamoate 2.43%
    aspartame 0.49%
    magnesium stearate 0.49%
    glycerol 2.91%
    soybean oil 16.75%
    Polyethylene Glycol 8000 15.29%
  • Dogs were randomly assigned to 4 treatment groups of 8 animals each, and one untreated control group of 8 animals. The dogs in the treatment groups were treated with the composition as described above on Day Zero as shown in Table 6:
  • TABLE 6
    Treatment Groups
    Group Treatment
    A Untreated control
    B 4.27% fluralaner chewable tablet 8 mg/kg bw
    C 4.27% fluralaner chewable tablet 10 mg/kg bw
    D 4.27% fluralaner chewable tablet 12 mg/kg bw
    E 4.27% fluralaner chewable tablet 20 mg/kg bw
  • The dogs were infested on Day −2 with approximately 50 adult unfed ticks (R. sanguineus) and on Day 28 and 56. Ticks were counted approximately 48 h post infestation and on Days 30 and 58 (approximately 48 hour after each post-treatment re-infestation) to evaluate the acaricidal activity in the treated groups.
  • Table 7 shows the observed tick counts:
  • TABLE 7
    Brown Dog Ticks (R. sanguineus) on dogs- Tick counts -
    Group Day 2 Day 30 Day 58
    A 21.25 23 25.9
    B 0 0 0
    C 0.125 0 0
    D 0 0 1.13
    E 0 0 0

Claims (17)

1-29. (canceled)
30. A soft chewable veterinary pharmaceutical composition comprising an isoxazoline compound of Formula (I)
Figure US20230320981A1-20231012-C00021
wherein
R1=halogen, CF3, OCF3, CN,
n=integer from 0 to 3,
R2=C1-C3-haloalkyl,
T=5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
Y=methyl, halomethyl, halogen, CN, NO2, NH2—C═S, or two adjacent radicals Y form together a chain, especially a three or four membered chain;
Q=X—NR3R4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals;
X=CH2, CH(CH3), CH(CN), CO, CS,
R3=hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
Figure US20230320981A1-20231012-C00022
Figure US20230320981A1-20231012-C00023
wherein ZA=hydrogen, halogen, cyano, halomethyl;
R4=hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;
Or R3 and R4 together form a substituent selected from the group consisting of:
Figure US20230320981A1-20231012-C00024
or a salt or solvate thereof, a solid carrier and a solvent wherein the solvent is 2.0-35.0% w/w of the composition with solubility for the isoxazoline compound and wherein the solid carrier is microcrystalline cellulose.
31. The soft chewable veterinary pharmaceutical composition of claim 30 further comprising pamoic acid or a pharmaceutically acceptable salt thereof.
32. The soft chewable veterinary pharmaceutical composition of claim 30 wherein the isoxazoline compound is fluralaner.
33. The soft chewable veterinary pharmaceutical composition of claim 30 wherein the composition comprises an additional pharmaceutically active compound.
34. A method of controlling parasite infestation in an animal comprising administering to the animal a therapeutically effective amount of the composition of claim 30.
35. A soft chewable veterinary pharmaceutical composition comprising an isoxazoline compound of Formula (I)
Figure US20230320981A1-20231012-C00025
wherein
R1=halogen, CF3, OCF3, CN,
n=integer from 0 to 3,
R2=C1-C3-haloalkyl,
T=5- or 6-membered ring, which is optionally substituted by one or more radicals Y,
Y=methyl, halomethyl, halogen, CN, NO2, NH2—C═S, or two adjacent radicals Y form together a chain, especially a three or four membered chain;
Q=X—NR3R4 or a 5-membered N-heteroaryl ring, which is optionally substituted by one or more radicals;
X=CH2, CH(CH3), CH(CN), CO, CS,
R3=hydrogen, methyl, haloethyl, halopropyl, halobutyl,
methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuryl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
Figure US20230320981A1-20231012-C00026
Figure US20230320981A1-20231012-C00027
wherein ZA=hydrogen, halogen, cyano, halomethyl;
R4=hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, methoxycarbonyl, methoxymethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;
Or R3 and R4 together form a substituent selected from the group consisting of:
Figure US20230320981A1-20231012-C00028
or a salt or solvate thereof, a solid carrier and a solvent wherein the solvent is 2.0-35.0% w/w of the composition with solubility for the isoxazoline compound and wherein the solvent is 2-pyrrolidone.
36. The soft chewable veterinary pharmaceutical composition of claim 35 further comprising pamoic acid or a pharmaceutically acceptable salt thereof.
37. The soft chewable veterinary pharmaceutical composition of claim 35 wherein the isoxazoline compound is fluralaner.
38. The soft chewable veterinary pharmaceutical composition of claim 35 wherein the composition comprises an additional pharmaceutically active compound.
39. A method of controlling parasite infestation in an animal comprising administering to the animal a therapeutically effective amount of the composition of claim 35.
40. A method of preparing the composition of claim 30 comprising dissolving the isoxazoline compound in the solvent and then adsorbing the resulting solution on to the solid carrier excipient.
41. The method of claim 40, where the solvent is 2-pyrrolidone or dimethyl acetamide.
42. The method of claim 40, where the solvent is 2-pyrrolidone.
43. The method of claim 40, where the solvent is dimethyl acetamide.
44. A method of preparing the composition of claim 35 comprising dissolving the isoxazoline compound in the solvent and then adsorbing the resulting solution on to the solid carrier excipient.
45. The method of claim 44, wherein the solid carrier is microcrystalline cellulose.
US18/335,415 2012-04-04 2023-06-15 Solid oral pharmaceutical compositions for isoxazoline compounds Pending US20230320981A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/335,415 US20230320981A1 (en) 2012-04-04 2023-06-15 Solid oral pharmaceutical compositions for isoxazoline compounds

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12163198 2012-04-04
EP12163198.0 2012-04-04
US201361782028P 2013-03-14 2013-03-14
PCT/EP2013/056992 WO2013150055A1 (en) 2012-04-04 2013-04-03 Solid oral pharmaceutical compositions for isoxazoline compounds
US201414390052A 2014-10-02 2014-10-02
US15/386,100 US20170100377A1 (en) 2012-04-04 2016-12-21 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds
US16/508,758 US20200000718A1 (en) 2012-04-04 2019-07-11 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds
US17/189,939 US11712416B2 (en) 2012-04-04 2021-03-02 Solid oral pharmaceutical compositions for isoxazoline compounds
US18/335,415 US20230320981A1 (en) 2012-04-04 2023-06-15 Solid oral pharmaceutical compositions for isoxazoline compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US17/189,939 Continuation US11712416B2 (en) 2012-04-04 2021-03-02 Solid oral pharmaceutical compositions for isoxazoline compounds

Publications (1)

Publication Number Publication Date
US20230320981A1 true US20230320981A1 (en) 2023-10-12

Family

ID=49300034

Family Applications (15)

Application Number Title Priority Date Filing Date
US14/390,040 Abandoned US20150057321A1 (en) 2012-04-04 2013-04-03 Soft chewable pharmaceutical products
US14/390,052 Active US9770440B2 (en) 2012-04-04 2013-04-03 Solid oral pharmaceutical compositions for isoxazoline compounds
US15/386,100 Abandoned US20170100377A1 (en) 2012-04-04 2016-12-21 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds
US15/390,244 Abandoned US20170105972A1 (en) 2012-04-04 2016-12-23 Soft chewable pharmaceutical products
US15/433,901 Abandoned US20170172918A1 (en) 2012-04-04 2017-02-15 Soft chewable pharmaceutical products
US15/433,840 Abandoned US20170172986A1 (en) 2012-04-04 2017-02-15 Soft chewable pharmaceutical products
US15/613,848 Abandoned US20170266165A1 (en) 2012-04-04 2017-06-05 Soft Chewable Pharmaceutical Products
US15/634,924 Active 2034-05-05 US11337917B2 (en) 2012-04-04 2017-06-27 Soft chewable pharmaceutical products
US15/982,904 Abandoned US20190117565A1 (en) 2012-04-04 2018-05-17 Soft Chewable Pharmaceutical Product
US15/982,879 Abandoned US20190117564A1 (en) 2012-04-04 2018-05-17 Soft Chewable Pharmaceutical Products
US16/296,490 Active US11285101B2 (en) 2012-04-04 2019-03-08 Soft chewable pharmaceutical products
US16/508,758 Abandoned US20200000718A1 (en) 2012-04-04 2019-07-11 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds
US17/189,939 Active 2033-07-19 US11712416B2 (en) 2012-04-04 2021-03-02 Solid oral pharmaceutical compositions for isoxazoline compounds
US17/648,841 Pending US20220142984A1 (en) 2012-04-04 2022-01-25 Soft Chewable Pharmaceutical Products
US18/335,415 Pending US20230320981A1 (en) 2012-04-04 2023-06-15 Solid oral pharmaceutical compositions for isoxazoline compounds

Family Applications Before (14)

Application Number Title Priority Date Filing Date
US14/390,040 Abandoned US20150057321A1 (en) 2012-04-04 2013-04-03 Soft chewable pharmaceutical products
US14/390,052 Active US9770440B2 (en) 2012-04-04 2013-04-03 Solid oral pharmaceutical compositions for isoxazoline compounds
US15/386,100 Abandoned US20170100377A1 (en) 2012-04-04 2016-12-21 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds
US15/390,244 Abandoned US20170105972A1 (en) 2012-04-04 2016-12-23 Soft chewable pharmaceutical products
US15/433,901 Abandoned US20170172918A1 (en) 2012-04-04 2017-02-15 Soft chewable pharmaceutical products
US15/433,840 Abandoned US20170172986A1 (en) 2012-04-04 2017-02-15 Soft chewable pharmaceutical products
US15/613,848 Abandoned US20170266165A1 (en) 2012-04-04 2017-06-05 Soft Chewable Pharmaceutical Products
US15/634,924 Active 2034-05-05 US11337917B2 (en) 2012-04-04 2017-06-27 Soft chewable pharmaceutical products
US15/982,904 Abandoned US20190117565A1 (en) 2012-04-04 2018-05-17 Soft Chewable Pharmaceutical Product
US15/982,879 Abandoned US20190117564A1 (en) 2012-04-04 2018-05-17 Soft Chewable Pharmaceutical Products
US16/296,490 Active US11285101B2 (en) 2012-04-04 2019-03-08 Soft chewable pharmaceutical products
US16/508,758 Abandoned US20200000718A1 (en) 2012-04-04 2019-07-11 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds
US17/189,939 Active 2033-07-19 US11712416B2 (en) 2012-04-04 2021-03-02 Solid oral pharmaceutical compositions for isoxazoline compounds
US17/648,841 Pending US20220142984A1 (en) 2012-04-04 2022-01-25 Soft Chewable Pharmaceutical Products

Country Status (13)

Country Link
US (15) US20150057321A1 (en)
EP (2) EP2833866B1 (en)
JP (2) JP6088637B2 (en)
KR (1) KR102077874B1 (en)
CN (4) CN109010296A (en)
AU (7) AU2013245008B2 (en)
BR (3) BR122022008957B1 (en)
CA (2) CA2868381C (en)
ES (1) ES2633611T5 (en)
NZ (1) NZ631100A (en)
RU (3) RU2632965C2 (en)
WO (2) WO2013150055A1 (en)
ZA (2) ZA201406968B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2811998T3 (en) 2012-02-06 2019-05-31 Merial Inc Parasiticidal oral veterinary compositions comprising systemically acting active agents, methods and uses thereof
US20150057321A1 (en) 2012-04-04 2015-02-26 Intervet Inc. Soft chewable pharmaceutical products
US9532946B2 (en) * 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
PT3079474T (en) * 2013-12-10 2019-09-10 Intervet Int Bv Antiparasitic use of isoxazoline compounds
EP4306168A3 (en) 2013-12-20 2024-03-13 Intervet International B.V. Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
HUE055444T2 (en) 2013-12-20 2021-11-29 Intervet Int Bv Use of isoxazoline derivatives for the treatment or prevention of arthropod infestations in poultry
CN106999421A (en) * 2014-11-03 2017-08-01 硕腾服务有限责任公司 Agreeable to the taste chewable veterinary composition
RU2709198C2 (en) 2014-12-22 2019-12-17 Интервет Интернэшнл Б.В. Use of isoxazoline compounds for demodecosis treatment
UY36570A (en) 2015-02-26 2016-10-31 Merial Inc INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES OF THE SAME
UY37137A (en) 2016-02-24 2017-09-29 Merial Inc ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
EP3532041A4 (en) * 2016-10-31 2020-06-24 The Scripps Research Institute Methods and compositions for preventing vector-borne disease transmission
CA3049952A1 (en) 2017-07-26 2019-01-31 Tgx Soft Chew, Llc Starch-free soft chew for veterinary applications
WO2020051106A1 (en) * 2018-09-05 2020-03-12 Zoetis Services Llc Palatable antiparasitic formulations
JP2022541916A (en) * 2019-07-22 2022-09-28 インターベット インターナショナル ベー． フェー． Soft Chewable Veterinary Dosage Form
WO2021122513A1 (en) * 2019-12-16 2021-06-24 Intervet International B.V. Composition for lice control
JP2024511957A (en) * 2021-03-11 2024-03-18 イン ザ ボウル アニマル ヘルス，インコーポレーテッド Oral canine feed and methods for controlling flea infestations in canines
WO2022192631A1 (en) * 2021-03-11 2022-09-15 In The Bowl Animal Health, Inc. Oral canine feed and methods for controlling tick infestations in a canine
WO2022271937A2 (en) * 2021-06-25 2022-12-29 In The Bowl Animal Health, Inc. Oral feline feed and methods for controlling flea infestations in a feline
CN113476419A (en) * 2021-08-17 2021-10-08 江苏恒丰强生物技术有限公司 Flurana chewable tablet for pets and preparation method thereof
WO2023086578A1 (en) * 2021-11-11 2023-05-19 Nutramax Laboratories, Inc. Soft chew
WO2023198476A1 (en) 2022-04-15 2023-10-19 Krka, D.D., Novo Mesto Soft chewable veterinary dosage form
CN117122571A (en) * 2022-05-20 2023-11-28 天津瑞普生物技术股份有限公司 Oral medicinal preparation for resisting parasitic infection, and preparation method and application thereof
FR3138315A1 (en) 2022-07-27 2024-02-02 Virbac Product for veterinary use and process for its manufacture

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819681A (en) * 1957-01-24 1959-09-09 Wellcome Found Improvements in and relating to quaternary ammonium compounds and the preparation thereof
US3486186A (en) 1967-05-08 1969-12-30 Hollymatic Corp Molding apparatus
US3887964A (en) * 1972-01-24 1975-06-10 Formax Inc Food patty molding machine
US3952478A (en) 1974-10-10 1976-04-27 Formax, Inc. Vacuum sheet applicator
US4054967A (en) 1975-10-20 1977-10-25 Formax, Inc. Food patty molding machine
US4284652A (en) 1977-01-24 1981-08-18 The Quaker Oats Company Matrix, product therewith, and process
US4182003A (en) 1978-02-28 1980-01-08 Formax, Inc. Food patty molding machine
US4338702A (en) 1979-03-29 1982-07-13 Holly Harry H Apparatus for making a ground food patty
US4334339A (en) 1980-05-12 1982-06-15 Hollymatic Corporation Mold device with movable compression insert
US4356595A (en) 1980-11-07 1982-11-02 Formax, Inc. Method and apparatus for molding food patties
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4343068A (en) 1981-01-19 1982-08-10 Holly James A Method and apparatus for unidirectional formation of a plug-formed patty with cleanout feature
US4372008A (en) 1981-04-23 1983-02-08 Formax, Inc. Food patty molding machine with multi-orifice fill passage and stripper plate
US4393085A (en) 1981-08-13 1983-07-12 General Foods Corporation Enzyme digestion for a dog food of improved palatability
IE53474B1 (en) 1981-09-17 1988-11-23 Warner Lambert Co A chewable comestible product and process for its production
CH657506A5 (en) 1981-12-10 1986-09-15 Hollymatic Ag PORTIONING MACHINE FOR FILLING CAVES WITH DEFORMABLE MATERIAL AND USE THEREOF.
US4535505A (en) 1982-11-23 1985-08-20 Holly Systems, Inc. Method and apparatus for forming a patty to accommodate tissue fiber flow
US4608731A (en) 1983-01-11 1986-09-02 Holly Systems, Inc. Food patty with improved void structure, shape, and strength and method and apparatus for forming said patty
US4609543A (en) 1983-11-14 1986-09-02 Nabisco Brands, Inc. Soft homogeneous antacid tablet
US4597135A (en) 1984-02-21 1986-07-01 Holly Systems, Inc. Food patty forming method and apparatus employing two or more agitator bars
DE3406497A1 (en) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner HIGHLY DISPERSAL PHARMACEUTICAL MULTI-COMPONENT SYSTEMS AND METHOD FOR THEIR PRODUCTION
US4768941A (en) 1986-06-16 1988-09-06 Hollymatic Corporation Food patty and machine and method for making thereof
US4697308A (en) 1986-10-29 1987-10-06 Formax, Inc. Patty molding mechanism for whole fiber food product
DE3636882C1 (en) 1986-10-30 1988-05-19 Schreiber Berthold Device for the fine-bubble introduction of a gas into a liquid
US4714620A (en) 1986-12-12 1987-12-22 Warner-Lambert Company Soft, sugarless aerated confectionery composition
US4780931A (en) 1987-02-13 1988-11-01 Marlen Research Corporation Feeding device for patty forming machine
US4821376A (en) 1988-06-02 1989-04-18 Formax, Inc. Seal-off for food patty molding machine with multi-orifice fill passage and stripper plate
US4997671A (en) 1988-09-09 1991-03-05 Nabisco Brands, Inc. Chewy dog snacks
US4872241A (en) 1988-10-31 1989-10-10 Formax, Inc. Patty molding mechanism for fibrous food product
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5021025A (en) 1989-09-12 1991-06-04 Wagner Richard C Method and machine for making food patties
US4975039A (en) 1989-09-18 1990-12-04 Dare Gary L Food molding and portioning apparatus
US4996743A (en) 1990-01-29 1991-03-05 Formax, Inc. Mold plate drive linkage
US5022888A (en) 1990-05-03 1991-06-11 Formax, Inc. Co-forming apparatus for food patty molding machine
US5262167A (en) 1990-12-20 1993-11-16 Basf Corporation Edible, non-baked low moisture cholestyramine composition
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
JP2575325B2 (en) 1991-06-18 1997-01-22 サクマ製菓株式会社 candy
US5439924A (en) 1991-12-23 1995-08-08 Virbac, Inc. Systemic control of parasites
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
PL185332B1 (en) 1994-05-20 2003-04-30 Janssen Pharmaceutica Nv Chewing tablets containing flubendazole for man accompanying animals
US5637313A (en) 1994-12-16 1997-06-10 Watson Laboratories, Inc. Chewable dosage forms
GB9508443D0 (en) 1995-04-26 1995-06-14 Gilbertson & Page Biscuit for working racing or sporting dogs
AUPN290395A0 (en) 1995-05-10 1995-06-01 Virbac (Australia) Pty Limited Canine anthelmintic preparation
US5578336A (en) 1995-06-07 1996-11-26 Monte; Woodrow C. Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making
PE10898A1 (en) 1995-06-13 1998-03-20 American Home Prod ORAL FORMULATIONS OF ETODOLAC S (+) -
US5606889A (en) 1995-09-19 1997-03-04 G & H Technology, Inc. Reusable initiator for use in triggering high-load actuators
DE19628776A1 (en) 1996-07-17 1998-01-22 Bayer Ag Oral granules of hexahydropyrazine derivatives
US5730650A (en) 1996-08-29 1998-03-24 Progressive Technology Of Wisconsin, Inc. Food patty molding machine
US5655436A (en) 1996-08-29 1997-08-12 Progressive Technology Of Manitowoc, Inc. Food patty molding machine
US6086940A (en) 1996-10-25 2000-07-11 T.F.H. Publications, Inc. High starch content dog chew
US6110521A (en) 1996-10-25 2000-08-29 T.F.H. Publications, Inc. Wheat and casein dog chew with modifiable texture
US5827565A (en) 1996-10-25 1998-10-27 T.F.H. Publications, Inc. Process for making an edible dog chew
US6093427A (en) 1997-09-03 2000-07-25 T.F.H.Publications, Inc. Vegetable-based dog chew
US5753255A (en) 1997-02-11 1998-05-19 Chavkin; Leonard Chewable molded tablet containing medicinally active substances
EP1900283A3 (en) 1998-03-23 2010-02-10 General Mills, Inc. Encapsulation of components into edible products
US6093441A (en) 1998-07-15 2000-07-25 Tfh Publications, Inc. Heat modifiable peanut dog chew
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
US6387381B2 (en) 1998-09-24 2002-05-14 Ez-Med Company Semi-moist oral delivery system
US6060078A (en) 1998-09-28 2000-05-09 Sae Han Pharm Co., Ltd. Chewable tablet and process for preparation thereof
WO2000027849A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
US6159516A (en) 1999-01-08 2000-12-12 Tfh Publication, Inc. Method of molding edible starch
GB9902073D0 (en) 1999-01-29 1999-03-24 Nestle Sa Chewy confectionery product
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
EP1103181A1 (en) * 1999-11-25 2001-05-30 Novartis AG Combination of N-phenyl-N'-benzoyl urea derivatives and avermectine compounds for parasite control
US6340672B1 (en) * 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
IT1317048B1 (en) 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti USE OF PAMOIC ACID OR ITS DERIVATIVE, OR ANALOGUE, FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DISEASES
DE10031044A1 (en) 2000-06-26 2002-01-03 Bayer Ag Endoparasiticidal agents for voluntary oral ingestion by animals
WO2002060255A2 (en) 2001-01-31 2002-08-08 Bayer Cropscience Gmbh Herbicide-safener combination based on isoxozoline carboxylate safeners
EP1247456A3 (en) 2001-02-28 2003-12-10 Pfizer Products Inc. Palatable pharmaceutical compositions for companion animals
GB0108485D0 (en) 2001-04-04 2001-05-23 Pfizer Ltd Combination therapy
ES2439725T3 (en) 2001-10-05 2014-01-24 Rubicon Scientific Llc Feed for animals that include active ingredients
CA2497452C (en) * 2002-08-13 2013-09-24 Akzo Nobel N.V. Compositions and process for delivering an additive
US20040151759A1 (en) * 2002-08-16 2004-08-05 Douglas Cleverly Non-animal product containing veterinary formulations
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
GB0219639D0 (en) 2002-08-22 2002-10-02 Prestwick Scient Capital Inc Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
US20040234579A1 (en) 2003-05-22 2004-11-25 Mark D. Finke, Inc. Dietary supplements and methods of preparing and administering dietary supplements
AR045142A1 (en) * 2003-07-30 2005-10-19 Novartis Ag BUEN SABOR DUCTILE MASTICABLE VETERINARY COMPOSITION
AU2008201605B2 (en) 2003-07-30 2010-04-29 Novartis Ag Palatable ductile chewable veterinary composition
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US7396819B2 (en) 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
WO2005016356A1 (en) 2003-08-08 2005-02-24 The Hartz Mountain Corporation Improved anthelmintic formulations
UA79571C2 (en) * 2003-12-04 2007-06-25 Basf Ag Metod for the protection of seeds from soil pests comprising
PE20051096A1 (en) 2004-02-04 2006-01-23 Novartis Ag SALT FORMS OF 4- (4-METHYLPIPERAZIN-1-ILMETHYL) -N- [4-METHYL-3- (4-PYRIDIN-3-IL) PYRIMIDIN-2-ILAMINO) PHENYL] -BENZAMIDE
WO2005085216A1 (en) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and noxious organism control agent
US20050226908A1 (en) 2004-04-07 2005-10-13 Akzo Nobel N.V. Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
CA2562015A1 (en) † 2004-04-09 2005-10-20 Janssen Pharmaceutica Nv Intermittent dosing regimens of apob secretion/mtp inhibitors for overweith and obese subjects
US20050234119A1 (en) 2004-04-16 2005-10-20 Soll Mark D Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
DE102004034043A1 (en) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Solid pharmaceutical composition containing mirtazapine
US7348027B2 (en) * 2005-04-08 2008-03-25 Bayer Healthcare Llc Taste masked veterinary formulation
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP1940380A2 (en) * 2005-05-20 2008-07-09 Pfizer Limited Synergistic combinations of non-steroidal antiinflammatory drugs with alpha-2 delta-ligands
JP5293921B2 (en) 2005-09-02 2013-09-18 日産化学工業株式会社 Isoxazoline-substituted benzamide compounds and pest control agents
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US20070128251A1 (en) 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
WO2007070606A2 (en) 2005-12-14 2007-06-21 E. I. Du Pont De Nemours And Company Isoxazolines for controlling invertebrate pests
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (en) * 2005-12-30 2013-10-21 Du Pont Isoxazolines for controlling invertebrate pests
CN101400662B (en) 2006-03-10 2012-11-14 日产化学工业株式会社 Substituted isoxazoline compound and pest control agent
KR20090005201A (en) 2006-04-20 2009-01-12 이 아이 듀폰 디 네모아 앤드 캄파니 Pyrazolines for controlling invertebrate pests
TWI342532B (en) * 2006-07-10 2011-05-21 Himax Tech Inc Method for generating a gamma table
JP2008044880A (en) * 2006-08-15 2008-02-28 Bayer Cropscience Ag Insecticidal isooxazolines
AU2007293068C1 (en) 2006-09-07 2013-09-19 Boehringer Ingelheim Animal Health USA Inc. Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations
CN101190223A (en) * 2006-11-29 2008-06-04 天津市润拓生物技术有限公司 Combantrin chewable tablets for dog or cat
US20090281059A1 (en) 2007-02-21 2009-11-12 Robert Falotico Coating for a medical device having an anti-thrombotic conjugate
EP2151437A4 (en) 2007-03-07 2012-05-02 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide compound and pest control agent
NZ580241A (en) 2007-04-10 2011-02-25 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
JP2008260691A (en) * 2007-04-10 2008-10-30 Bayer Cropscience Ag Insecticidal arylisoxazoline derivative
AU2007352619B2 (en) 2007-05-03 2013-07-18 Boehringer Ingelheim Animal Health USA Inc. Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds
WO2008134819A1 (en) * 2007-05-07 2008-11-13 Jurox Pty Ltd Improved dosage form and process
BRPI0811635B1 (en) 2007-05-15 2018-11-06 Aventis Agriculture arylazol-2-yl cyanoethylamino compounds, processes for making them and using them
US20080293645A1 (en) 2007-05-25 2008-11-27 Schneider Lawrence F Antiparasitic combination and method for treating domestic animals
MX2009013469A (en) 2007-06-13 2010-01-20 Du Pont Isoxazoline insecticides.
TWI430995B (en) * 2007-06-26 2014-03-21 Du Pont Naphthalene isoxazoline invertebrate pest control agents
NO2957284T3 (en) * 2007-06-27 2018-06-16
WO2009005015A1 (en) 2007-06-29 2009-01-08 Nissan Chemical Industries, Ltd. Substituted isoxazoline or enone oxime compound, and pest control agent
ITCL20070039A1 (en) 2007-07-10 2009-01-11 Michele Neri CONSTANT PRESSURE CYLINDER WITH EXTRUDED PROBOSCIDE TUBE AND DOSING VALVE, ATTACHED TO A STRUCTURE ON WHICH ROLLS, ACTIVATED BY A SOURCE OF CONTROLLED PRESSURE, USED IN PARTICULAR FOR THE EXTRUSION AND PROCESSING OF ALL PASTA:
TWI556741B (en) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 Isoxazoline compositions and their use as antiparasitics
WO2009035004A1 (en) 2007-09-10 2009-03-19 Nissan Chemical Industries, Ltd. Substituted isoxazoline compound and pest control agent
AU2008303129B2 (en) 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
ES2399572T3 (en) 2007-10-03 2013-04-02 E. I. Du Pont De Nemours And Company Naxaphthalene isoxazoline compounds for the control of invertebrate pests
TWI411395B (en) 2007-12-24 2013-10-11 Syngenta Participations Ag Insecticidal compounds
BRPI0915665B1 (en) 2008-07-09 2018-01-02 Basf Se PESTICIDATED MIXTURES, METHODS FOR PROTECTING PLANTS FROM ATTACK OR INSECTS, ACARIDES OR NEMATOES, TO CONTROL INSECTS, ARACNIDS OR NEMATOIDS, USE OF PESTICIDES OR PARASITICIDES
EP2308857B1 (en) 2008-07-09 2016-04-27 Nissan Chemical Industries, Ltd. Process for production of isoxazoline-substituted benzoic acid amide compound
EP2317856A1 (en) 2008-07-09 2011-05-11 Basf Se Pesticidal mixtures comprising isoxazoline compounds ii
JP2010026724A (en) * 2008-07-17 2010-02-04 Fujitsu Ltd Web page providing apparatus, method for interlocking web page with ranking and program thereof
JP2012501989A (en) 2008-09-04 2012-01-26 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト Insecticidal compound
US9820977B2 (en) 2008-10-03 2017-11-21 Bayer Healthcare Llc Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent
EP2364301B1 (en) 2008-11-14 2015-09-02 Merial Limited Enantiomerically enriched aryloazol-2-yl cyanoethylamino paraciticidal compounds
NZ612417A (en) 2008-11-19 2015-02-27 Merial Inc Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
AU2009322206B2 (en) 2008-12-04 2015-03-05 Boehringer Ingelheim Animal Health USA Inc. Dimeric avermectin and milbemycin derivatives
CA2747060A1 (en) 2008-12-18 2010-07-15 Novartis Ag Isoxazolines derivatives and their use as pesticide
WO2010070068A2 (en) * 2008-12-19 2010-06-24 Novartis Ag Organic compounds
WO2010072602A1 (en) * 2008-12-23 2010-07-01 Basf Se Substituted amidine compounds for combating animal pests
WO2010084067A2 (en) 2009-01-22 2010-07-29 Syngenta Participations Ag Insecticidal compounds
US20120030841A1 (en) 2009-04-01 2012-02-02 Basf Se Isoxazoline compounds for combating invertebrate pests
NZ584629A (en) * 2009-04-15 2010-12-24 Jurox Pty Ltd Anthelmintic formulation
US9040583B2 (en) 2009-07-22 2015-05-26 Temple University-Of The Commonwealth System Of Higher Education Treatment of disorders associated with G protein-coupled receptor 35 (GPR35)
TWI487486B (en) * 2009-12-01 2015-06-11 Syngenta Participations Ag Insecticidal compounds based on isoxazoline derivatives
PT2513104E (en) 2009-12-17 2016-06-03 Merial Inc Antiparasitic dihydroazole compounds and compositions comprising same
ES2546417T3 (en) 2010-02-01 2015-09-23 Basf Se Substituted ketone isoxazoline compounds and derivatives to combat animal pests
NZ601446A (en) 2010-02-25 2014-03-28 Syngenta Participations Ag Pesticidal mixtures containing isoxazoline derivatives and insecticide or nematoicidal biological agent
AU2011236510A1 (en) 2010-04-08 2012-10-11 Zoetis Llc Substituted 3,5- di phenyl - isoxazoline derivatives as insecticides and acaricides
CN101919857B (en) * 2010-05-05 2012-05-30 四川宝盛康药业有限公司 Novel compound albendazole preparation, application thereof and preparation method thereof
MA34247B1 (en) 2010-05-27 2013-05-02 Du Pont 4- [5- [3-CHLORO-5- (TRIFLUOROMETHYL) PHENYL] -4,5-DIHYDRO-5- (TRIFLUOROMETHYL) -3-ISOXAZOLYL] -N- [2-OXO-2 - [(2)) CRYSTALLINE FORM , 2,2-TRIFLUOROETHYL) AMINO] ETHYL] -1-NAPHTHALENECARBOXAMIDE
US20130261069A1 (en) 2010-06-09 2013-10-03 Syngenta Crop Protection Llc Pesticidal mixtures comprising isoxazoline derivatives
EP2579724A2 (en) 2010-06-09 2013-04-17 Syngenta Participations AG Pesticidal mixtures including isoxazoline derivatives
EP2579725A2 (en) 2010-06-09 2013-04-17 Syngenta Participations AG Pesticidal mixtures including isoxazoline derivatives
UY33403A (en) 2010-06-17 2011-12-30 Novartis Ag ORGANIC COMPOUNDS WITH NEW ISOXAZOLINES, THEIR N-OXIDES, S-OXIDES AND SALTS
DK178277B1 (en) 2010-06-18 2015-10-26 Novartis Tiergesundheit Ag Diaryloxazoline compounds for the control of fish lice
AU2011271429B2 (en) 2010-06-30 2016-04-21 Upsher-Smith Laboratories, Llc Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
WO2012007426A1 (en) 2010-07-13 2012-01-19 Basf Se Azoline substituted isoxazoline benzamide compounds for combating animal pests
JP2012046486A (en) * 2010-07-30 2012-03-08 Sumitomo Chemical Co Ltd Animal ectoparasite-controlling agent
RU2551354C2 (en) 2010-08-05 2015-05-20 Зоетис ЭлЭлСи Isoxazoline derivatives as anti-parasitic agents
AU2011306489B2 (en) 2010-09-24 2015-11-05 Zoetis Services Llc Isoxazoline oximes as antiparasitic agents
US9744127B2 (en) 2010-10-12 2017-08-29 Bayer Intellectual Property Gmbh Non-starch based soft chewables
US9173870B2 (en) * 2010-12-27 2015-11-03 Intervet Inc. Topical localized isoxazoline formulation
ES2715000T3 (en) 2011-09-12 2019-05-31 Merial Inc Parasiticidal compositions comprising an active isoxazoline agent, methods and uses thereof
JP2014533735A (en) * 2011-11-29 2014-12-15 ノバルティス アーゲー Use of aryl derivatives to control ectoparasites
PL2811998T3 (en) * 2012-02-06 2019-05-31 Merial Inc Parasiticidal oral veterinary compositions comprising systemically acting active agents, methods and uses thereof
US20150057321A1 (en) * 2012-04-04 2015-02-26 Intervet Inc. Soft chewable pharmaceutical products
US9532946B2 (en) 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units

Also Published As

Publication number Publication date
AU2019246812A1 (en) 2019-10-31
RU2632965C2 (en) 2017-10-11
BR112014024833B1 (en) 2022-10-04
AU2013245008B2 (en) 2017-03-30
US20190201332A1 (en) 2019-07-04
EP2833867A1 (en) 2015-02-11
WO2013150052A1 (en) 2013-10-10
CN109010296A (en) 2018-12-18
CA2869242C (en) 2020-04-14
CN108685894A (en) 2018-10-23
WO2013150055A1 (en) 2013-10-10
RU2017133665A3 (en) 2021-01-25
AU2013245008A1 (en) 2014-10-16
AU2013245011A1 (en) 2014-10-23
EP2833866B1 (en) 2018-11-21
US20150057239A1 (en) 2015-02-26
JP6148724B2 (en) 2017-06-14
BR112014024833A2 (en) 2017-06-20
AU2017204246A1 (en) 2017-07-13
BR112014024832B1 (en) 2022-05-31
AU2019246812B2 (en) 2021-08-12
CN108685894B (en) 2022-04-26
AU2013245011B2 (en) 2017-11-23
CN104203214A (en) 2014-12-10
NZ631100A (en) 2016-06-24
BR112014024832A2 (en) 2017-06-20
US20190117565A1 (en) 2019-04-25
KR102077874B1 (en) 2020-02-14
AU2017268487A1 (en) 2017-12-14
RU2646483C2 (en) 2018-03-05
AU2019213359A1 (en) 2019-08-29
US20170172986A1 (en) 2017-06-22
US20150057321A1 (en) 2015-02-26
JP2015514103A (en) 2015-05-18
US20170105972A1 (en) 2017-04-20
US11712416B2 (en) 2023-08-01
US20170290766A1 (en) 2017-10-12
CN104203214B (en) 2018-05-25
US20170172918A1 (en) 2017-06-22
BR122022008957B1 (en) 2023-02-07
US20190117564A1 (en) 2019-04-25
ZA201406968B (en) 2015-06-24
US20170100377A1 (en) 2017-04-13
ES2633611T5 (en) 2023-09-26
CA2869242A1 (en) 2013-10-10
RU2014144001A (en) 2016-05-27
EP2833866A1 (en) 2015-02-11
US20200000718A1 (en) 2020-01-02
RU2765231C2 (en) 2022-01-26
ES2633611T3 (en) 2017-09-22
EP2833867B1 (en) 2017-05-17
CA2868381A1 (en) 2013-10-10
KR20140141633A (en) 2014-12-10
US11337917B2 (en) 2022-05-24
CN104334159A (en) 2015-02-04
US9770440B2 (en) 2017-09-26
US20210177749A1 (en) 2021-06-17
US20220142984A1 (en) 2022-05-12
JP2015512435A (en) 2015-04-27
JP6088637B2 (en) 2017-03-01
US20170266165A1 (en) 2017-09-21
AU2021266292A1 (en) 2021-12-09
BR112014024833A8 (en) 2022-08-09
ZA201608614B (en) 2023-11-29
CA2868381C (en) 2020-07-07
EP2833867B2 (en) 2023-05-10
US11285101B2 (en) 2022-03-29
RU2017133665A (en) 2019-02-07
RU2014144360A (en) 2016-05-27

Similar Documents

Publication Publication Date Title
US11712416B2 (en) Solid oral pharmaceutical compositions for isoxazoline compounds
US10864195B2 (en) Topical localized isoxazoline formulation
US20150011596A1 (en) Topical localized isoxazoline formulation comprising glycofurol
RU2772279C2 (en) Solid pharmaceutical compositions for oral administration based on isooxazoline compounds
US20200390688A1 (en) Long-acting topical formulation and method of use thereof
KR20190112825A (en) Topical localized isoxazoline formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTERVET INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FREEHAUF, KEITH;WALDRON, NIKI;LUTZ, JURGEN;AND OTHERS;SIGNING DATES FROM 20130319 TO 20130325;REEL/FRAME:063962/0284

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: INTERVET INC., NEW JERSEY

Free format text: CHANGE OF ADDRESS;ASSIGNOR:INTERVET INC.;REEL/FRAME:065028/0818

Effective date: 20230912